OTCPK:GNML.F

Stock Analysis Report

Executive Summary

Genomma Lab Internacional, S.A.B. de C.V.


Snowflake Analysis

Reasonable growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Genomma Lab Internacional. de's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GNML.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

GNML.F

-0.9%

US Pharmaceuticals

0.06%

US Market


1 Year Return

n/a

GNML.F

6.1%

US Pharmaceuticals

19.3%

US Market

Return vs Industry: Insufficient data to determine how GNML.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GNML.F performed against the US Market.


Shareholder returns

GNML.FIndustryMarket
7 Day0%-0.9%0.06%
30 Day11.7%-3.4%1.7%
90 Dayn/a5.6%9.0%
1 Yearn/a8.8%6.1%21.8%19.3%
3 Year-9.2%-9.2%24.9%16.1%49.5%39.9%
5 Year-3.5%-3.5%21.5%9.1%73.1%54.1%

Price Volatility Vs. Market

How volatile is Genomma Lab Internacional. de's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Genomma Lab Internacional. de undervalued compared to its fair value and its price relative to the market?

29.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GNML.F ($1.09) is trading below our estimate of fair value ($1.55)

Significantly Below Fair Value: GNML.F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GNML.F is poor value based on its PE Ratio (25.1x) compared to the Pharmaceuticals industry average (21.6x).

PE vs Market: GNML.F is poor value based on its PE Ratio (25.1x) compared to the US market (18.5x).


Price to Earnings Growth Ratio

PEG Ratio: GNML.F is poor value based on its PEG Ratio (1.1x)


Price to Book Ratio

PB vs Industry: GNML.F is good value based on its PB Ratio (2.8x) compared to the US Pharmaceuticals industry average (3.1x).


Next Steps

Future Growth

How is Genomma Lab Internacional. de forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

23.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GNML.F's forecast earnings growth (23.5% per year) is above the savings rate (1.7%).

Earnings vs Market: GNML.F's earnings (23.5% per year) are forecast to grow faster than the US market (14.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GNML.F's revenue (7.2% per year) is forecast to grow slower than the US market (7.6% per year).

High Growth Revenue: GNML.F's revenue (7.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GNML.F's Return on Equity is forecast to be high in 3 years time (20.8%)


Next Steps

Past Performance

How has Genomma Lab Internacional. de performed over the past 5 years?

10.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GNML.F has high quality earnings.

Growing Profit Margin: GNML.F's current net profit margins (7.4%) are lower than last year (10.8%).


Past Earnings Growth Analysis

Earnings Trend: GNML.F's earnings have grown by 10.5% per year over the past 5 years.

Accelerating Growth: GNML.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GNML.F had negative earnings growth (-24.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.2%).


Return on Equity

High ROE: GNML.F's Return on Equity (11.7%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Genomma Lab Internacional. de's financial position?


Financial Position Analysis

Short Term Liabilities: GNML.F's short term assets (MX$9.9B) exceed its short term liabilities (MX$5.5B).

Long Term Liabilities: GNML.F's short term assets (MX$9.9B) exceed its long term liabilities (MX$5.6B).


Debt to Equity History and Analysis

Debt Level: GNML.F's debt to equity ratio (74.3%) is considered high.

Reducing Debt: GNML.F's debt to equity ratio has increased from 64.1% to 74.3% over the past 5 years.

Debt Coverage: GNML.F's debt is well covered by operating cash flow (22.1%).

Interest Coverage: GNML.F's interest payments on its debt are well covered by EBIT (4.1x coverage).


Balance Sheet

Inventory Level: GNML.F has a high level of physical assets or inventory.

Debt Coverage by Assets: GNML.F's debt is covered by short term assets (assets are 1.7x debt).


Next Steps

Dividend

What is Genomma Lab Internacional. de's current dividend yield, its reliability and sustainability?

3.55%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GNML.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GNML.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GNML.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GNML.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: GNML.F is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GNML.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Jorge Luis Brake Valderrama 0

1.4yrs

Tenure

Mr. Jorge Luis Brake Valderrama is the Chief Executive Officer at Genomma Lab Internacional SAB de CV since September 10, 2018. He held the position of Senior Vice President of Global Operations at Laureat ...


Leadership Team

NamePositionTenureCompensationOwnership
Jorge Luis Brake Valderrama
Chief Executive Officer1.4yrsno datano data
Antonio Zamora Galland
Executive VP & CFO0yrsno datano data
Juan Marco Sparvieri
Executive VP & COO1.5yrsno datano data
Enrique González Casillas
Head of Investor Relations0yrsno datano data
Ruben Alberto Luna Porres
Legal Officer0yrsno datano data
César Alejandro Jaramillo López
Executive Vice President of Marketing2.1yrsno datano data
Alejandro Bastón Patiño
Executive Vice-President of Media & Institutional Affairs0yrsno datano data
Patricia Velázquez
Chief of Security0yrsno datano data
Marco Francisco Forastieri Muñoz
Secretary0yrsno datano data
Efraín Tapia Córdova
Deputy Secretary2.8yrsno datano data

1.8yrs

Average Tenure

Experienced Management: GNML.F's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.2%.


Top Shareholders

Company Information

Genomma Lab Internacional, S.A.B. de C.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genomma Lab Internacional, S.A.B. de C.V.
  • Ticker: GNML.F
  • Exchange: OTCPK
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: Mex$22.200b
  • Listing Market Cap: Mex$1.180b
  • Shares outstanding: 1.01b
  • Website: https://www.genommalab.com

Number of Employees


Location

  • Genomma Lab Internacional, S.A.B. de C.V.
  • Antonio Dovali Jaime # 70
  • Piso 2 Torre C
  • Mexico City
  • Distrito Federal
  • 1210
  • Mexico

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LAB BBMV (Bolsa Mexicana de Valores)YesSeries B Variable SharesMXMXNJun 2008
GEKADB (Deutsche Boerse AG)YesSeries B Variable SharesDEEURJun 2008
GNML.FOTCPK (Pink Sheets LLC)YesSeries B Variable SharesUSUSDJun 2008

Biography

Genomma Lab Internacional, S.A.B. de C.V. together with its subsidiaries, engages in the research, development, and marketing of pharmaceutical, over the counter, and cosmetic products in Mexico and internationally. The company was founded in 1996 and is based in Mexico City, Mexico. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/21 00:52
End of Day Share Price2020/02/04 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.